Wednesday, April 29, 2020
More negative data for checkpoint inhibition in treatment of mCRPC | THE "NEW" PROSTATE CANCER INFOLINK
More negative data for checkpoint inhibition in treatment of mCRPC | THE "NEW" PROSTATE CANCER INFOLINK: Alas … once again we hear that the combination of androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clini…
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment